Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
NCT ID: NCT06448611
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
25 participants
OBSERVATIONAL
2024-07-01
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Can any residual disease be found in the form of circulating tumoral cells in blood samples of patients treated with surgery and radiotherapy for a resectable, stage I to III Merkel cell carcinoma ? When possible, the circulating tumoral cells count will be compared to the one realized in a blood sample of the same patient before surgery and radiotherapy.
Participants will :
* Have a blood sample taken before surgery (if the patient is addressed to our center early enough),
* Have a blood sample taken immediately after surgery and radiotherapy (for all).
* Two additional blood samples will be taken during the 6-months and 12-months visit to set up a biobank.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
NCT05062096
Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
NCT06039033
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02514824
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
NCT01886235
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Another goal will be to track changes in the number of circulating tumoral cells before and after treatment in patients with stage I to III Merkel cell carcinoma, who have had a blood sample taken before starting treatment.
Investigators will also set up a biobank, which is a collection of blood samples taken every six months for one year. These samples will help with future research.
The study will include patients over 18 years old with stage I to III Merkel cell carcinoma, treated at the Dermatology Departments of Montpellier and Nimes University Hospitals. Investigators will not include pregnant or breastfeeding women, patients not covered by social security, those under court protection, those unable to give consent, or those with stage IV Merkel cell carcinoma or stage I to III Merkel cell carcinoma where complete remission is not possible. All patients will give free and informed consent to participate.
Patients will be divided into two groups based on when they are referred to the university hospital for treatment.
Group A: If the tumor is fully removed before the patient is referred to the hospital.
Group B: If the tumor is still present when referred to the hospital. This can happen if:
* Only a biopsy has been done to confirm the tumor.
* The tumor was removed but it is stage III with lymph node involvement. Both scenarios will not affect the main goal (checking for circulating tumoral cells after treatment). However, the change in circulating tumoral cell numbers before and after treatment can only be checked in Group B, where patients had a blood sample taken before treatment.
Both groups will have follow-up visits at 6 and 12 months. The main endpoint will be the circulating tumoral cell detection rate, which is the presence of circulating tumoral cells in their blood right after surgery and radiotherapy. Another measure will be the change in the number of circulating tumoral cells before and after treatment for those who had a blood sample taken before starting treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
Entire cohort
Blood Test
Research and quantification of Circulating Tumor Cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Test
Research and quantification of Circulating Tumor Cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients managed for stage I to III Merkel cell carcinoma,
* For whom complete remission by complete surgical resection is planned (group B) or has been achieved recently, within 6 weeks prior to the inclusion visit (group A).
Exclusion Criteria
* Failure to obtain written informed consent after a reflection period
* Participant in another research study with an ongoing exclusion period
* Not affiliated to a social security scheme
* Persons under court protection
* Patients unable to give consent, protected adults, vulnerable persons
* Stage IV disease or stage I to III disease for which complete remission is not envisaged
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL23_0452
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.